Cardiac hypertrophy and aortic distensibility in essential hypertension

M E Safar1, S Laurent, R A Asmar

  • 1Diagnosis Center, Broussais Hospital, Paris, France.

Insights

Hypertension can cause cardiac hypertrophy by reducing aortic distensibility. Certain blood pressure medications improve arterial stiffness, aiding in the reversal of cardiac hypertrophy.

Area of Science:

  • Cardiovascular Medicine
  • Hypertension Research
  • Vascular Physiology

Background:

  • Reduced aortic distensibility and compliance are implicated in cardiac hypertrophy development within hypertensive states.
  • In borderline hypertension, altered aortic distensibility shows weak correlation with septal hypertrophy, a marker for cardiac hypertrophy.
  • Sustained essential hypertension exhibits a strong correlation between cardiac hypertrophy and increased aortic rigidity.

Purpose of the Study:

  • To investigate the relationship between aortic distensibility, arterial stiffness, and cardiac hypertrophy in hypertensive patients.
  • To evaluate the impact of different antihypertensive treatments on arterial stiffness and cardiac hypertrophy.
  • To understand the role of aortic rigidity modifications in the regression of cardiac hypertrophy.

Main Methods:

  • Analysis of aortic distensibility and compliance indices in hypertensive patient cohorts.
  • Assessment of septal hypertrophy as a marker for cardiac hypertrophy.
  • Comparison of the effects of dihydralazine-like substances, calcium-entry blockers, and converting-enzyme inhibitors on arterial stiffness.

Main Results:

  • Aortic distensibility alterations are observed in borderline hypertension but poorly correlate with septal hypertrophy.
  • A strong correlation exists between increased aortic rigidity and cardiac hypertrophy in sustained essential hypertension.
  • Calcium-entry blockers and converting-enzyme inhibitors improve arterial stiffness, unlike dihydralazine-like substances, at equivalent blood pressure reduction.

Conclusions:

  • Aortic rigidity plays a significant role in the development of cardiac hypertrophy in sustained hypertension.
  • Improving arterial stiffness through specific antihypertensive medications may be crucial for the regression of cardiac hypertrophy.
  • Modifications in aortic rigidity are a key factor to consider when aiming for cardiac hypertrophy reversion in hypertension management.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...